Cambrex Corp., an East Rutherford-based manufacturer of pharmaceuticals, announced a new pilot plant at its manufacturing and R&D site in Paullo, Italy.“We currently have a product portfolio comprising over 70 generic APIs, which are manufactured under cGMP, for the global generic pharmaceutical industry,” Aldo Magnini, managing director, Cambrex Milan, said in a prepared statement. “We have invested in the pilot plant to expand our small-scale volume offering for customers worldwide and to give us greater speed, flexibility and capacity in this market space.”
Cambrex is planning to upgrade the pilot plant in 2017 to support the production of its products.